Introduction
It is a known phamarcogenetic phenomenon that drug responses differ significantly between different races. Genetic mutation in a gene which codes for a drug-metabolizing enzyme can cause enzyme variations with high, low or no activity. The cytochrome P450 enzymes, a superfamily of hemoproteins, are the terminal oxidases of the mixed function oxidase system found on the membrane of the smooth endoplasmic reticulum preferentially expressed in the centrilobular area of the liver [1] . The cytochrome P450 isoenzymes in families 1-3 are responsible for 70-80% of all phase I-dependent metabolism of clinically used drugs [2] [3] [4] and also participate in the metabolism of a large number of xenobiotic chemicals. The human CYP2Cs are among the most important subfamilies within the CYP superfamily, which metabolize nearly 20% of clinically used drugs.
CYP2C9 is the most important member of the CYP2Cs, and it hydroxylates about 15% of drugs [5] in current clinical use. The CYP2C9 gene codes for a significant drug-metabolizing enzyme which has a series of prescribed drugs as its substrates, including drugs with a narrow therapeutic index such as S-warfarin, tolbutamide and phenytoin [6, 7] . Impaired CYP2C9 catalytic activity can cause difficulties in drug efficacy and toxicity. Because of their narrow therapeutic index, dosage adjustment of these drugs based on CYP2C9 genotype, especially at the beginning of therapy, could help to lower the risk of concentration-dependent drug toxicity in variant carriers. CYP2C9 also metabolizes other routinely prescribed drugs such as acenocoumarol, losartan, glipizide, and a large number of nonsteroidal anti-inflammatory drugs, including diclofenac and ibuprofen [5, 8] . The enzyme activity of CYP2C9 is therefore a critical factor in pharmacotherapy.
To date, though more than 30 variant CYP2C9 alleles have been identified, CYP2C9*2 and *3 are the most prevalent and can influence drug clearance and drug response. In vitro, for some drugs, the substrate affinity of CYP2C9*2 (Arg144Cys) variants is not significantly affected [5] ; but for some other drugs such as acenocoumarol, the catalytic activity of CYP2C9*2 is severely decreased [9] . There is a significant reduction of the catalytic activity in the CYP2C9*3 (Ile359Leu) variant, with only around 10% of the intrinsic clearance of the wild-type enzyme for most CYP2C9 substrates [9, 10] . In addition, the frequencies of the related SNPs are different in different races. In Caucasians, higher frequencies of CYP2C9*2 and CYP2C9*3 alleles are observed (10.7% and 7.4% respectively) [11] , compared with African-Americans (1% and 0.5%, respectively) [12] . The CYP2C9*2 allele has rarely been detected in Asian populations. It has been found to have a frequency of 13% in Iran [13] but has not been detected in other major populations including those of Korea and Japan. The allelic frequency of the CYP2C9*3 variant is also significantly lower among Asians compared with other groups.
While the frequencies of mutant alleles of CYP2C9, in particular the CYP2C9*2 and CYP2C9*3 polymorphisms, have been studied extensively in other major populations, there is no comprehensive information on polymorphisms of the gene for the Chinese Han population. As the largest population in the world (nearly 20%), the Chinese Han population is spread over the third largest populated area with a land mass of about 9.6 million square kilometer. In addition, the Han have an extremely long and complex demographic history and the population stratification arising from the interplay of different geographic areas will therefore have influenced the polymorphism pattern. A previous study by our group found that a cryptic borderline was observable between the Southern Han and the Northern Han populations [14] . However, no polymorphism study of the CYP2C9 gene focusing on the different geographic Han populations has been carried out to date.
To establish a database of CYP2C9 allele frequencies for the healthy Chinese Han population, which would be useful for personalized medicine, we decided to systematically screen the polymorphisms of the CYP2C9 gene including the 5'-flanking region, all exons and their neighboring intron regions and the 3' UTR in the four different geographic Chinese Han populations covering the north, south, east and west of Chinese mainland.
Result
We detected a total of 27 different polymorphisms from 400 Chinese Han population samples, 3 of which were novel. All the allele and genotype frequencies were analyzed using the SHEsis analysis platform and were found to be in equilibrium with the Hardy-Weinberg equation. We found five polymorphisms in the 5'-flanking region. Tfsitescan analysis (http://www.ifti.org) revealed no altered transcription factor binding efficiency. In the coding region, we found seven polymorphisms, including 1 novel synonymous one (T1137 → C, p.379Tyr → -Tyr). 11 polymorphisms were detected in the introns, one of which was novel (42461 T N C). We did some splice analysis of the intronic (or exonic) SNPs, but still obtained no positive results. We also found three polymorphisms in the 3'-UTR region, one of which was novel (1739-1740ATdel) (Fig. 1) , and which has the potential to influence the stability of CYP2C9 mRNA. We made a statistical comparison of all the polymorphism frequencies in the four different geographic populations. The comparison revealed some SNPs with significant differences (p b 0.0001) between the four geographic populations. The frequencies of all the polymorphisms are summarized in Table 1 and the p-values for the four populations in Table 2 .
More than 30 CYP2C9 alleles and 400 genotypes have been reported. In our study, we found 6 CYP2C9 alleles and 11 genotypes in the mainland Chinese Han population. The most frequent alleles were the wild-type allele *1(92%), followed by the *3 allele (4.6%) and the *8 allele (1.8%). Some allele frequencies were low (b1%), such as the *2 allele (0.6%), the *11 allele (0.1%) and the *31 allele (0.9%). Some alleles had significantly different frequencies across the four different geographical populations, such as the *2 and *8 alleles. We found these two SNPs in Shanghai and Shenyang populations, but not in those of Shantou or Xi'an areas. Allele *11 was detected only in Xi'an population, and allele *31 was detected in Shantou and Shenyang populations. The results are shown in Table 3 . The genotype frequencies are shown in Table 4 .
We compared the allele and genotype frequencies with other major populations, including Asians and non-Asians, as shown in Table 5 . Most populations we analyzed had 3 major alleles namely allele *1, allele *2, and allele *3, each with different frequencies, possibly reflecting the differences in racial make-up and the different geographical areas. We also performed the haplotype analysis, but it was a lack that we didn't find any interesting results.
Discussion
CYP2C9 plays a very important role in cytochrome P450 genetic diversity and in the metabolism of prescribed drugs. It would therefore be advantageous to have an assessment of a patient's CYP2C9 metabolic status before initiation of therapy to identify the risk of nonresponse to therapy or toxic drug effects and to ensure optimal dosage. While the frequencies of mutant alleles of CYP2C9 have been studied in other populations, little comprehensive information on genetic polymorphisms of the CYP2C9 gene has been available for the Chinese Han population. Our study provides new data on CYP2C9 polymorphism in this population and compares the incidence of polymorphisms among subjects from four different geographic areas of Chinese mainland as well as with those from other different racial and ethnic populations. This could contribute significantly toward a better understanding of the polymorphisms of CYP2C9 and of the potential database for personalized medicine in the Chinese Han population.
One novel SNP was detected in the 3'-UTR region and it may have an impact on the stabilization of mRNA transcription. The CYP2C9 *8 and *11 were first found in Asian populations while they have already been found in African-American [15, 16] . CYP2C9*8 (Arg150His) and CYP2C9*11 (Arg335Trp) can both cause a decrease in the activity of CYP2C9 in vivo [17, 18] . While in vitro studies showed that CYP2C9*8 (Arg150His) had an increase of its activity comparing with a decreased activity of CYP2C9*11 (Arg335Trp) [15, 16] . Still, the functional activity of CYP2C9*31 (Ile327Thr) is unknown both in vivo and in vitro. This has relevance for the study of CYP2C9 gene polymorphisms in the Chinese Han population and could be helpful for future pharmacogenomics and pharmacokinetics studies in Asian populations generally.
In our polymorphism analysis, the prevalence of *2 and *3 is in accordance with previous reports [19] . Some allele and genotype frequencies showed differences among the four different populations, which differ in their cultural variants and other factors, such as living environment, dietary habits, and even folk customs. Systematic analysis of the connections between the polymorphisms and the different geographical populations can give us a map of the polymorphism distribution over the whole Han population and would be useful for personalized medicine in China.
We compared the allele and genotype polymorphisms in the Chinese Han population with other ethnic populations and found that the allele frequencies detected in our Han population are similar to those in Asian groups, such as the Tamilnadu and South Indian populations [20, 21] . However, CYP2C9*2, which we detected in our study, has not been reported in the Korean and Japanese populations [22, 23] , and CYP2C9*3, which we also identified, is absent in the Iranian population [13] . Several alleles (*8, *11) are not found in other Asian populations such as Korean and Japanese, while the Beninese and Belgian population have *11 (2.7% and 0.4%, respectively) [24] . As discussed above, the three alleles (*3, *8, *11) can decrease CYP2C9 activity, and we calculated their total frequency across the Chinese population at 6.5%. Significant differences were found between the Han Chinese and non-Asian populations. These results indicate significant differences in polymorphism distributions between Asian and non-Asian populations. In summary, we systematically screened the polymorphisms of the whole CYP2C9 gene in four different geographical Han populations of mainland China. This is the first systematic screening of genetic polymorphisms of CYP2C9 in the Chinese Han population, and is the largest CYP2C9 genotyping study using direct sequencing in China. We have provided new data on the genetic polymorphism of the CYP2C9 gene, which can help to establish a database for further functional research and for personalized medicine in the Chinese population.
Materials and methods

Subjects
The study subjects consisted of 400 Chinese healthy unrelated volunteers from four geographical area of the Chinese mainland: 100 subjects from Xi'an city which lies in the west of china; 100 subjects from Shanghai city which lies in the east of china; 100 subjects from Shenyang city which lies in the north of china; 100 subjects from Shantou city which lies in the south of china. Each group of 100 subjects consisted of 50 males and 50 females between 18 and 53 years of age. All subjects were judged to be in good health in terms of their medical history and following a physical examination. All participants gave ethnic information about themselves, confirming their parents and grandparents to be of the same origin. The four different populations were frequency-matched to each other in terms of age and sex. An explanation of the study was given to the participating subjects and they gave a standard informed consent, which was reviewed and approved by the Shanghai Ethical Committee of Human Genetic Resources. All subjects were Han Chinese in origin.
Polymerase chain reaction conditions and DNA sequencing
The systematic polymorphism screening was performed using direct sequencing. Genomic DNA was isolated from peripheral blood using the standard procedure. The PCR primers were designed to amplify the 2000 bp of the 5'-flanking regions and all exons of the CYP2C9 gene. To insure that all the regions we chose were analyzed, the PCR amplification regions in the 5'-flanking region overlapped each other. The primers are listed in Table 6 . The PCR was carried out on the Gene Amp® PCR system 9700 (Applied Biosystems, CA, USA) in a total volume of 15 μL containing 10 ng of genomic DNA, 10 mM TrisHCl (pH 8.3), 50 mM KCl, 1.5-3.0 mM MgCl 2 , 200 mM dNTP, 1 mM of each primer and 0.25U Taq DNA polymerase. The cycling protocol consisted of denaturation at 95°C for 1 min, followed by 30-35 cycles at 95°C for 30 s, 50-65°C for 1 min, 72°C for 1 min, and a final extension at 72°C for 10 min. Preparation of DNA for sequencing included incubation of PCR products with 0.1 U of shrimp alkaline phosphatase (Roche, Basel, Switzerland) and 0.5 U of exonuclease I (New England Biolabs Inc., MA, USA) at 37°C for 45 min, followed by heat inactivation at 85°C for 20 min. The PCR products were sequenced using an ABI Prism® BigDye Terminator Cycle Sequencing Kit, version 3.1 (Applied Biosystems, CA, USA) on an ABI Prism 3100 sequencer. 
Statistical analysis
All of the polymorphisms were named based on the nucleotide reference sequence (NG_008385.1) and the protein reference sequences (NP_000762.2). Allele and genotype frequencies were calculated by the counting method. Comparisons of allele and genotype frequencies among different geographic populations or between the Chinese population and other ethnic populations were done using χ 2 tests or Fisher's exact tests with a significance level set at 0.05. Hardy-Weinberg equilibrium calculations and p-value between each of two loci were performed using the SHEsis analysis platform (http://analysis.bio-x.cn/myAnalysis.php).
Automated splice site analysis
The strengths of splice sites for the corresponding splicing mutations were evaluated using web-based software (https://splice. cmh.edu).
Analysis of functional sequences in the promoter region
The transcription factor binding analysis of the polymorphisms in the 5'untranslated region (UTR) was performed on the web-based Tfsitescan software based on the transcription factor binding sites database. The normal and mutant sequences were analyzed separately. The influence of the polymorphisms was inferred by the comparison of the results of the normal and mutated sequences.
